key: cord-0290006-g22ky065
authors: Li, Lei; Honda-Okubo, Yoshikazu; Huang, Ying; Jang, Hyesun; Carlock, Michael A.; Baldwin, Jeremy; Piplani, Sakshi; Bebin-Blackwell, Anne G.; Forgacs, David; Sakamoto, Kaori; Stella, Alberto; Turville, Stuart; Chataway, Tim; Colella, Alex; Triccas, Jamie; Ross, Ted M; Petrovsky, Nikolai
title: Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection
date: 2021-07-05
journal: bioRxiv
DOI: 10.1101/2021.07.03.451026
sha: 80d06637f702387565ede79c135ccd5ab7b8a0b7
doc_id: 290006
cord_uid: g22ky065

The development of a safe and effective vaccine is a key requirement to overcoming the COVID-19 pandemic. Recombinant proteins represent the most reliable and safe vaccine approach but generally require a suitable adjuvant for robust and durable immunity. We used the SARS-CoV-2 genomic sequence and in silico structural modelling to design a recombinant spike protein vaccine (Covax-19™). A synthetic gene encoding the spike extracellular domain (ECD) was inserted into a baculovirus backbone to express the protein in insect cell cultures. The spike ECD was formulated with Advax-SM adjuvant and first tested for immunogenicity in C57BL/6 and BALB/c mice. The Advax-SM adjuvanted vaccine induced high titers of binding antibody against spike protein that were able to neutralise the original wildtype virus on which the vaccine was based as well as the variant B.1.1.7 lineage virus. The Covax-19 vaccine also induced potent spike-specific CD4+ and CD8+ memory T-cells with a dominant Th1 phenotype, and this was shown to be associated with cytotoxic T lymphocyte killing of spike labelled target cells in vivo. Ferrets immunised with Covax-19 vaccine intramuscularly twice 2 weeks apart made spike receptor binding domain (RBD) IgG and were protected against an intranasal challenge with SARS-CoV-2 virus 2 weeks after the second immunisation. Notably, ferrets that received two 25 or 50μg doses of Covax-19 vaccine had no detectable virus in their lungs or in nasal washes at day 3 post-challenge, suggesting the possibility that Covax-19 vaccine may in addition to protection against lung infection also have the potential to block virus transmission. This data supports advancement of Covax-19 vaccine into human clinical trials.

In mid-January 2020, we identified the putative spike protein from the SARS-CoV-2 genome sequence 48 in NCBI (accession number: NC 045512) [20] . Given the homology of the spike proteins (76.4% 49 sequence identity), SARS-CoV-1 was used as a template to model the SARS-CoV-2 spike protein. We 50 performed a PSI-BLAST search against the Protein Data Bank (PDB) Database for 3D modelling template 51 selection. Using the SARS-CoV-1 structure (PDB-ID 6ACC) [21] we performed structural homology 52 modelling using Modeller9.23 (https://salilab.org/modeller/) to obtain a 3D structure of SARS-CoV-2 53 spike protein ( Figure 1A ). The quality of the spike protein model was evaluated using GA341 and DOPE 54 score, and the model was assessed using the SWISS-MODEL structure assessment server 55

Virus-serum was then added onto ACE2-HEK 293T cells seeded at 2,500 cells per well in a 384-well 137 tissue culture plate a day before. Following spinoculation at 1200xg for 1 h at 18°C, the cells were 138 moved to 37°C for a further 72 h. Entry of pseudotyped particles was assessed by imaging GFP-positive 139 cells and total cell numbers imaged through live nuclei counter staining using NucBlue (Invitrogen). 140

Total cell counts and % GFP-positive cells were acquired using the InCell imaging platform followed by 141 enumeration with InCarta high content image analysis software (Cytiva). Neutralisation was measured 142 by reduction in % GFP expression relative to control group infected with the virus particles without 143 any serum treatment. 144

145

Murine T-cell response 146 BALB/c and BL6 mice were sacrificed, and individual spleens were collected one to two weeks after 147 the last immunisation. Single-cell suspension in sterile PBS+3% FCS was prepared using a 70 µm easy 148 strainer (Greiner Bio-One) with a 5 ml syringe plunger. Isolated spleen cells were pelleted and 149 incubated in red blood cell (RBC) lysis buffer. For Cytometric Bead Array (CBA) assay, splenocytes were 150 cultured at 5 x 10 5 cells/well in 96-well plates with 3 µg/ml of rSp antigen [corresponding to CoV-2 (Wuhan) reference sequence Q13 to P1209] at 37°C and 5% CO2. Two days later, the 152 supernatants were harvested and cytokine concentrations determined by mouse Th1/Th2/Th17 CBA 153 (BD) and analysed by FCAP array Software (BD). In addition to CBA assay, enzyme-linked immune 154 absorbent spot (ELISPOT) assay was performed using mouse Interlukin-2 (IL-2), Interlukin-4 (IL-4) or 155

Interferon gamma (IFN-γ) ELISPOT set (BD PharMingen) or Interlukin-17 (IL-17) antibodies (BioLegend) 156 according to the manufacturer's instruction. Briefly, single-cell suspensions were prepared from 157 spleens of mice and plated in Millipore MultiScreen-HA 96-well filter plates (Millipore) pre-coated with 158 anti-mouse IL-2, IL-4, IL-17 or IFN-γ antibodies overnight at 4°C and blocked by RPMI-1640 containing 159 10% FBS. Cells were incubated for 48 h in the presence or absence of rSp protein at 37°C and 5% CO2. 160

Wells were washed and incubated with biotinylated labelled anti-mouse IL-2, IL-4, IL-17 or IFN-γ 161 antibody at room temperature (RT). After washing, wells were incubated with HRP-conjugated 162 Streptavidin (BD Biosciences) for 1 h at RT. Wells were extensively washed again and developed with 163 3-amino-9-ethyl-carbazole (AEC) substrate set (BD Biosciences). After drying, spots were counted on 164 an ImmunoSpot ELISPOT reader (CTL ImmunoSpot Reader, software version 5. 1.36) . Finally, a T-cell 165 proliferation assay was performed by incubating collected mice spleen cells for 7 min at RT with 5 µM 166 expressed as the ratio of divided daughter cells to total T-cells, expressed as a percentage, by analogy 171 to calculation of a stimulation index in thymidine proliferation assays. 172

Functional CD8 + T cell response was determined by performing in vivo CTL assays, as described earlier 175

[28]. Briefly, naïve syngeneic target spleen cells were left unpulsed or pulsed for 2 h in humidified CO2 176 incubator at 37°C with 5µM H-2K b -restricted Sp539-546 (VNFNFNGL) synthetic peptide [29] (DGpeptide, 177

Hangzhou, China). Unpulsed (control) and peptide (antigen)-pulsed spleen cells were labelled with 0.5 178 µM CFSE (CFSE low ) and 5 µM CFSE (CFSE high ), respectively. Then, naïve syngeneic and immunised mice 179 were adoptively transferred with 4×10 6 cells of a 1:1 mix of control-to-antigen-pulsed target spleen 180 cells. Eighteen (18) 

Based on the high binding score (-57.6 kcal/mol) seen from docking our 3D-model of spike protein to 291 several putative receptors, we predicted ACE2 as the human entry receptor for SARS-CoV-2 ( Figure  292 1B) [24] . This was soon confirmed by other groups using in vitro assays [19] . Based on this spike protein 293 model, we sought to design a stable soluble secreted spike protein trimer for use as our vaccine 294 immunogen. We designed a synthetic gene comprising the spike protein extracellular domain (ECD) 295 together with N-terminal honeybee melittin signal sequence (HBMss) to ensure protein secretion and 296 attached a hexa-histidine tag at the C-terminal end to assist with protein purification ( Figure 1A) . 297

Molecular dynamic simulation performed on the spike protein ECD vaccine construct confirmed its 298 ability to form a stable trimer despite the lack of the transmembrane and cytoplasmic domains and 299 the absence of any large trimerisation domain tag as used by others ( Figure 1C ). The spike ECD gene 300 construct was constituted into a baculovirus backbone, and the subsequent virus then used to 301 transfect two insect cell lines (SF9 and Tni). While both cell lines successfully secreted the protein 302 construct, higher protein expression was obtained in the Tni cells and these were used for subsequent 303 production of a recombinant spike protein which was purified using a nickel affinity column and sterile 304 filtration. The final protein product had a purity of ~ 90% by SDS-PAGE ( Figure 1D & E) and was sterile 305 with a low endotoxin and residual DNA content (data not shown). 306 307

The serum anti-spike protein response of BL6 mice immunised with rSp alone was dominated by IgG1, 309 a T helper 2 (Th2) isotype, whilst in Advax-SM adjuvanted groups the response was characterised by 310 a switch to more IgG2b/c and IgG3 against spike ( Figure 2B) . Overall, Advax-SM adjuvant was 311 associated with a much higher anti-spike IgG2/IgG1 ratio consistent with a Th1-biased response 312 Figure 1) . 320

Spike RBD-binding antibodies have been reported to correlate with SARS-CoV-2 virus neutralisation 321 [30] . There was a high correlation for each IgG subclass between the level of spike and RBD binding 322 antibodies by ELISA, suggesting a significant proportion of spike antibodies induced by our rSp antigen 323 were directed against the RBD region. RBD-binding IgG was almost undetectable in mice immunised 324 with rSp alone, although these mice did exhibit some RBD-binding IgM. Notably, the Advax-SM 325 adjuvant increased the spike IgG response but particularly favoured production of RBD-binding 326 antibodies when expressed as a ratio of the total spike IgG response ( Figure 2C) . 327 BALB/c mice, which have an overall Th2 bias, exclusively made IgG1 when immunised with rSp alone. 328

Similar to what was seen in BL6 mice, in BALB/c mice Advax-SM adjuvanted rSp induced a switch from 329 anti-spike IgG1 to IgG2b/c and IgG3 production The increased IgG2b/c and IgG3 induced by the Advax-330 SM adjuvant was equivalent to the reduction in IgG1. Interestingly, BALB/c mice had a low ratio of 331 RBD to spike IgG, with IgM the dominant RBD-binding antibody rather than IgG. This contrasted with 332 the high RBD to spike IgG ratio seen in the BL6 mice (Supplementary Figure 2) . 333

To determine whether the spike antibodies induced by our vaccine could neutralise virus infectivity, 334 immune sera were tested in both a pseudotyped lentivirus assay (pseudovirus assay) and a SARS-CoV-335 Figure 4) . This could reflect that pseudotype neutralisation assays are 368 unique at two levels, they utilise greater numbers of viral particles to enable cellular transduction and 369 infection over a 3-day period with repeated rounds of viral replication. Hence, each assay measures 372 different but important parameters of viral infection, providing clues as to the ability of immune sera 373 to neutralize first-round viral entry vs. a replicative infection 374 375

Cytokine production was measured in culture supernatants of rSp-stimulated splenocytes obtained 377 from immunised mice. In BL6 mice, rSp-stimulated IL-2, IFN-γ and TNF-α was significantly higher in the 378 Advax-SM group, consistent with their Th1 bias ( Figure 4A-C) . Similarly, in BALB/c mice, there was 379 higher rSp-stimulated IFN-γ and TNF-α in the Advax-SM group (Figure 4A-C) . In BALB/c mice, rSp-380 stimulated IL-4, IL-6 and IL-10 production was highest in the rSp-alone immunised group, which also 381 exhibited low IFN-γ and TNF production, consistent with a Th2 bias (Figure 4D-F) . IL-17 was modestly 382 increased in Advax-SM adjuvanted rSp groups in both BL6 and BALB/c mice ( Figure 4G) . Overall, rSp-383 alone groups exhibited a Th2 cytokine bias, while Advax-SM groups exhibited a Th1 bias with an 384 increased IFN-γ/IL-4 ratio ( Figure 4H ). ELISPOT assays on splenocytes from immunised mice confirmed 385 significantly higher frequencies of IL-2 and IFN-γ secreting T cells in response to rSp stimulation in the 386 Advax-SM groups (Figure 5A-B) . Anti-spike IL-4-producing T cells were significantly higher in BALB/c 387 mice, consistent with their Th2 bias ( Figure 5C ). Anti-spike IL-17-producing T-cells were also higher in 388 the Advax-SM group in BL6 mice ( Figure 5D) . 389 390 Spike-specific CD4+ and CD8+ T cell memory cell population were further assessed using a CFSE-dye 391 dilution proliferation in response to rSp stimulation. Notably, anti-spike CD8 T cell responses were 392 markedly increased in both BALB/c and BL6 mice that had received Advax-SM adjuvanted rSp ( Figure  393 6), consistent with the high levels of anti-spike CTL activity also seen in mice receiving this formulation 394 (Supplementary Figure 1) . There was also a clear trend to higher anti-spike CD4 T cell responses in 395 mice that had received Advax-SM adjuvanted rSp, although this difference only reached significance 396 in the Balb/c group (Figure 6) . 397 398

Having confirmed that the formulation of rSp with Advax-SM adjuvant gave optimal immunogenicity 400 whether measured by neutralising antibody, T cell cytokines or CTL responses in mice, we next moved 401 to test the efficacy of this optimised formulation in a ferret infection challenge model. Ferrets were Sera was obtained 2 weeks after the first and second immunisation and measured for IgG to RBD. 408

Anti-RBD IgG was detectable even 2 weeks after the first dose in all rSp-immunised groups and levels 409

were further increased 2 weeks after the second dose in those animals that received the second rSp 410 dose ( Figure 7B) Whilst primary ciliated or goblet cells from nasopharyngeal tissue might be the most physiologically 499 relevant cell type to use in neutralisation assays, high-throughput serology screening using air-500 interface cultures is not feasible. Whilst pseudotyping assays can be performed outside of a BSL3 501 facility, they measure only a single round of spike-mediated cellular fusion and, hence, do not mimic 502 a natural infection where there are multiple rounds of entry and replication. RBD-binding antibody 503 assays work on the presumption that antibodies that block spike protein from binding to ACE2 should IgG titres have not prevented virus replication in the nasal mucosa, suggesting either that such 506 antibodies fail to prevent virus binding or entry or that they fail to get access to the nasal epithelium. 507 508 How do results compare for these assays? Previous studies on convalescent patients have reported a 509 positive correlation between spike-specific IgG and both pseudotype virus and live virus 510 neutralisation. In our study, there was a poor correlation between the pseudovirus and live virus 511 assays, suggesting they measure different determinants of neutralisation. The live virus assay 512 measures the ability to block cell infection by a small pool of viral particles across 3 days of culture. 513

The pseudotype assay uses a large pool of virus particles as a surrogate for a single spike-driven fusion 514 event. In our study, total spike antibody ELISA predicted pseudotype neutralisation better than the 515 RBD-binding ELISA. Interestingly, in BALB/c but not BL6 mice, there was a positive correlation between 516 total anti-rSp IgM (but not anti-RBD IgM) with neutralisation titres. Elite donors with high 517 neutralisation titres in human convalescent cohorts surprisingly achieved this via anti-viral IgM (S. 518

Turville, personal communication). There is still no established correlate of COVID-19 protection that 519 has been confirmed in either animal models or humans. The fact that different assays seem to yield 520 different results suggests that the identification of a correlate based upon simple antibody protection 521 may not be straightforward. 522 523 Unless a vaccine is able to induce potent sterilising immunity, some SARS-CoV-2 virus will inevitably 524 enter cells in the nasal mucosa, where antibodies will not be able to reach it and begin to replicate. In 525 the face of uncertainty over antibody protection and rapidly waning circulating SARS-CoV-2 antibody 526 levels, a strong CD8 T cell response with interferon production and CTL activity is likely to be important of splenocytes using anti-mouse cytokine antibody-coated plates by ELISPOT. Statistical analysis was 754 done by Mann-Whitney test. *; p < 0.05, **; p < 0.01, ***; p < 0.001, ns; not significant. 755 -rSp 50µg + Advax-SM -rSp 25µg + Advax-SM -rSp 12.5µg + Advax-SM -rSp 50µg + Advax-SM (Single) -rH7HA + Advax-SM -Saline Control

Characteristics of SARS-CoV-2 and COVID-19

Weekly Operational Update on COVID-19

Pathology and pathogenesis of severe acute respiratory syndrome. The American 590 journal of pathology

Covid-19: Is a second wave hitting Europe?

Fast-spreading UK virus variant raises alarms

Evolution of the COVID-19 vaccine development landscape

The COVID-19 vaccine 596 development landscape

Next-generation vaccine platforms for COVID-19

Out of the frying pan and into the fire? Due diligence warranted for ADE in

COVID-19. Microbes and Infection

COVID-19 vaccine safety

Vaccine adjuvant systems: enhancing 604 the efficacy of sub-unit protein antigens

Targeting the innate immune response with improved vaccine 606 adjuvants

Adjuvant strategies to improve vaccination of the elderly population. Current 608 Opinion in Pharmacology

Severe acute respiratory 610 syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced

A new coronavirus associated with human 629 respiratory disease in China

Cryo-EM structure of the SARS coronavirus spike glycoprotein 631 in complex with its host cell receptor ACE2

Mechanisms of host receptor adaptation by severe 633 acute respiratory syndrome coronavirus

The HDOCK server for integrated protein-protein docking

Mobilization of HIV 640 spread by diaphanous 2 dependent filopodia in infected dendritic cells

Efficient lentiviral 643 transduction of Herpesvirus saimiri immortalized T cells as a model for gene therapy in primary 644 immunodeficiencies

SARS-CoV-2 cell 646 entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Advax delta inulin adjuvant overcomes immune immaturity 649 in neonatal mice thereby allowing single-dose influenza vaccine protection

Identification of murine CD8 T 652 cell epitopes in codon-optimized SARS-associated coronavirus spike protein

SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus 656 neutralization

Vaccine development for an imminent pandemic: why we should worry, what we 658 must do

Activation and evasion of type I interferon 660 responses by SARS-CoV-2

I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV

CD8+ T cell efficacy in vaccination and disease. Nature medicine

Adjuvants enhancing cross-presentation by dendritic cells: the

Delta inulin polysaccharide 668 adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets

Antibody-dependent enhancement and SARS-CoV-2 671 vaccines and therapies

Disease severity dictates SARS-CoV-2-specific 673 neutralizing antibody responses in COVID-19

Molecular clamp 675 stabilised Spike protein for protection against SARS-CoV-2

Effect of convalescent plasma therapy 678 on viral shedding and survival in patients with coronavirus disease 2019

Covid-19: Eli Lilly pauses antibody trial for safety reasons

COVID-19 antibodies on trial

SARS-CoV-2 entry factors 683 are highly expressed in nasal epithelial cells together with innate immune genes

Clinical and immunological features of 686 severe and moderate coronavirus disease 2019

COVID-19 severity correlates 689 with airway epithelium-immune cell interactions identified by single-cell analysis

Elevated exhaustion levels and 692 reduced functional diversity of T cells in peripheral blood may predict severe progression

High IL-6/IFN-γ ratio could be associated with severe 695 disease in COVID-19 patients

COVID-19 vaccines: modes of immune activation and future challenges

Potential adjuvants for the development of a SARS-CoV-2 vaccine based on 699 experimental results from similar coronaviruses

Construction and immunogenic studies of a mFc 701 fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 702 infection

Infection and rapid transmission of

SARS-CoV-2 in ferrets

Towards 706 effective COVID-19 vaccines: Updates, perspectives and challenges

Viral vectors as vaccine platforms: 709 deployment in sight

DNA and RNA-based vaccines: principles, progress and prospects

Ferrets were 764 challenged with SAR-CoV-2 virus (1 X 10^5 PFU) 14 days after last immunisation. Blood was collected 765 at day -28, -14. Lungs were collected 3 days post challenge for immunopathology. Lungs and nasal 766 washes were collected 3 days post challenge for viral titres. (B) ELISA for Ferret anti-RBD IgG 767 antibodies. (C) Haematoxylin & Eosin (H&E) (i-vi) and anti-SARS-CoV-2

Advax-SM adjuvant enhances Cytotoxic T lymphocyte (CTL) activity and 771 overcomes dominant Th2-bias compared to rSp antigen alone or together with Advax-SM adjuvant

Female BL6 mice were immunised i.m. twice at 2-week intervals with 1 µg rSp alone or with Advax-773 SM or 50 µg Al(OH)3 adjuvant. Blood samples were collected at 2 weeks and spleens at 4 weeks after 774 the last immunisation. Shown are CTL functional assay (A) and ELISA (B) results (mean + SD). Statistical 775 analysis was done by Mann-Whitney test

Supplementary Figure 2: Co-administration of Advax-SM adjuvant enhances both vaccine-induced

Shown are anti-rSp and anti-RBD antibodies 779 measured by ELISA (mean + SD) in BALB/c mice

Supplementary Figure 3: Neutralisation antibody titres determined by SARS-CoV-2 (S-CoV-2) Spike 783 pseudotyped lentivirus-based platform and S-CoV-2 live virus. Correlation of NT titre and ELISA OD 784 value in BL6 mice (A) and BALB/c mice (B)

Supplementary Figure 4: Correlation of S-CoV-2 and pseudotype neutralisation assays. 787 sections were assessed by board-certified veterinary pathologist blinded to the groups for lung injury 792 score and number of lesions